Tacrolimus in pediatric renal transplantation

Transplantation

Volumn 62, Issue 12, 1996, Pages 1752-1758

  Shapiro, Ron ^a,b   Scantlebury, Velma P ^a   Jordan, Mark L ^c   Vivas, Carlos ^c   Gritsch, H Albin ^c   Ellis, Demetrius ^d   Gilboa, Nisan ^d   Lombardozzi Lane, Susan ^d   Irish, William ^a   Fung, John J ^a   Hakala, Thomas R ^c   Simmons, Richard L ^d   Starzl, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Falk Building ^*  (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADOLESCENT; CHILD; CONFERENCE PAPER; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; TACROLIMUS;

EID: 8044234362     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612270-00010     Document Type: Conference Paper

References (37)

1. Starzl TE, Todo S, Fung J, et al. FK506 for human liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000.
2. Todo S, Fung JJ, Starzl TE. Liver, kidney, and thoracic organ transplantation under FK506. Ann Surg 1990; 212: 295.
3. Fung JJ, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs. cyclosporine. Transplant Proc 1991; 23(6): 2977.
4. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with primary orthotopic liver transplantation under FK506 immunosuppression. Ann Surg 1994; 220; 297.
5. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
6. U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
7. Starzl TE, Fung JJ, Jordan M, et al. Kidney transplantation under FK506. JAMA 1990; 264: 63.
8. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995; 59: 485.
9. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506/prednisone vs FK506/azathioprine/ prednisone in renal transplant patients. Transplant Proc 1995; 27(1): 814.
10. Jordan M, Shapiro R, Vivas C, et al. FK506 rescue for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57(6): 860.
11. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II FK506 multicenter concentration control study. One-year follow-up. Transplant Proc 1995; 27(1): 809.
12. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: results of late phase II study. Transplant Proc 1993; 25 (1 Pt 1): 649.
13. Ochiai T, Ishibashi M, Fukao K, et al. Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc 1995; 27(1): 50.
14. Schleibner S, Kraus M, Wagner K, et al. FK 506 versus cyclosporin in the prevention of renal allograft rejection - European pilot study: six-week results. Transpl Int 1995; 8: 86.
15. Demetris AJ, Banner B, Fung JJ, Shapiro R, Jordan M, Starzl TE. Histopathology of human renal allograft function under FK506: a comparison with cyclosporine. Transplant Proc 1991; 23 (1 Pt 2): 944.
16. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993; 17(1): 60.
17. Shapiro R, Fung JJ, Jain A, Parks P, Todo S, Starzl TE. The side effects of FK 506 in humans. Transplant Proc 1990; 22: 35.
18. Scantlebury V, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 versus cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23(6): 3169.
19. Yoshimura N, Nakai I, Ohmori Y, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis 1988; 12: 11.
20. Boudreaux J, McHugh L, Canafax D, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376.
21. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995; 60(12); 1384.
22. Shapiro R, Jordan ML, Scantlebury VP, et al. Tacrolimus in renal transplantation. Transplant Proc 1996; 28(4): 2117.
23. Starzl TE. Pediatric renal transplantation under FK506 immunosuppression. Transplant Proc 1991; 23: 3075.
24. Schneck F, Jordan M, Jensen C, et al. Pediatric renal transplantation under FK506 immunosuppression. J Urol 1992; 147: 1585.
25. Ellis D, Shapiro R, Jordan ML, et al. Comparison of FK506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 1994; 8: 193.
26. Scantlebury V, Shapiro R, Tzakis A, et al. Pediatric kidney transplantation at the University of Pittsburgh. Transplant Proc 1994; 26(1): 46.
27. Shapiro R, Tzakis A, Scantlebury V, et al. Improving results of pediatric kidney transplantation. J Am Coll Surg 1994; 179(4): 424.
28. Shapiro R, Scantlebury V, Jordan ML, et al. FK506 in pediatric kidney transplantation - primary and rescue experience. Pediatr Nephrol 1995; 9: S43.
29. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506 in renal transplantation - a comparison between double and triple drug therapy. Clin Transplant 1994; 8: 508.
30. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985; 106: 522.
31. Grossi P, Kusne S, Rinaldo C, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cmv-free recipients of livers from seropositive donors. Transplantation 1996; 61: 1659.
32. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991; 23(6): 3054.
33. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994; 57(6): 848.
34. Todo S, Tzakis A, Reyes J, et al. Small intestinal transplantation in humans with or without the colon. Transplantation 1994; 57(6): 840.
35. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK506 rescue in chronic graft versus host disease after bone marrow transplantation. Transplant Proc 1991; 23(6): 3225.
36. Masaoka T, Shibata H, Kakishita E, Kanamaru A, Takemoto Y, Moriyama Y. Phase II study of FK506 for allogeneic bone marrow transplantation. Transplant Proc 1991; 23(6): 3228.
37. Tzakis AG, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 1990; 336: 402.